Award
NIH Reporter #1R44HD122555-01
Anti-Sense Oligonucleotide Therapy for HNRNPH2 Neurodevelopmental Disorder
Recipient
ALPHAROSE THERAPEUTICS INC.
Award Amount
$313,208.00
Ceiling
$313,208.00
Awarded
September 17, 2026
Identifier
1R44HD122555-01
NIH-funded project supporting AlphaRose Therapeutics’ development of antisense oligonucleotide therapy for HNRNPH2 neurodevelopmental disorder, with the goal of advancing a candidate toward clinical trials.
Description
Fast-Track SBIR project to advance antisense oligonucleotide candidates toward an Investigational New Drug application. The project includes manufacturing and testing candidate ASOs, in vivo efficacy studies to select a lead, and planned follow-on manufacturing, safety, biodistribution, and IND preparation work.